Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
-
Publication number: 20140249175Abstract: The present invention relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.Type: ApplicationFiled: April 7, 2014Publication date: September 4, 2014Applicant: GENERICS [UK] LIMITEDInventors: Vinayak Govind GORE, Bindu MANOJKUMAR, Dattatraya SHINDE, Dattatrey KOKANE
-
Publication number: 20140248327Abstract: An interventional medical device and manufacturing method thereof. The interventional medical device comprises: a stent body (1); a surface of the stent body (1) being provided with a drug releasing structure (3), and drug in the drug releasing structure (3) being drug for suppressing proliferation of adventitial fibroblasts and a drug for suppressing proliferation of intimal and/or smooth muscle cells. In use, after interventional medical device is implanted into a human body, the drug for suppressing proliferation of adventitial fibroblasts carried thereon can promote the compensatory expansion of the vessel, and the drug for suppressing proliferation of intimal cells and/or smooth muscle cells carried thereon can suppress intimal proliferation of the vessel. The combination of the two kinds of drugs greatly reduces the occurrence rate of in-stent restenosis.Type: ApplicationFiled: January 16, 2012Publication date: September 4, 2014Applicant: SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.Inventors: Dadong Zhang, Xu Cai, Chengyun Yue, Junfei Li, Yan Hu, Peng Huang, Zhirong Tang, Qiyi Luo
-
Publication number: 20140249143Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.Type: ApplicationFiled: October 19, 2012Publication date: September 4, 2014Applicant: GlaxoSmithKline LLCInventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
-
Patent number: 8822462Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.Type: GrantFiled: January 28, 2010Date of Patent: September 2, 2014Assignee: Emory UniversityInventors: Stephen F. Traynelis, Dennis C. Liotta, Rose M. Santangelo, Ethel C. Garnier
-
Publication number: 20140243356Abstract: The present invention provides methods of identifying an agent that modulates an oncogenic signaling pathway in a biological sample by generating a translational profile of gene translational levels in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.Type: ApplicationFiled: February 7, 2014Publication date: August 28, 2014Applicant: The Regents of the University of CaliforniaInventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind
-
Publication number: 20140242144Abstract: Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney.Type: ApplicationFiled: April 30, 2014Publication date: August 28, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Krishanankutty Sudhir, Joanne M. Ferguson
-
Publication number: 20140242162Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.Type: ApplicationFiled: October 3, 2012Publication date: August 28, 2014Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
-
Publication number: 20140243311Abstract: The present invention provides compounds represented by the general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is cyano or the like; R2 and R3 are hydrogen or the like; R4 is C1-6 alkyl or the like; R5 is C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, cycloalkyl-C1-6 alkyl, aralkyl or the like; R6 and R7 are each hydrogen, C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, C1-6 alkoxy-C1-6 alkyl, R12R13N—C1-6 alkyl or the like, which exhibit potent dopamine D2 receptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.Type: ApplicationFiled: March 12, 2012Publication date: August 28, 2014Applicant: KISSEI PHARMACEUTICAL CO., LTD.Inventors: Toshihiro Nishimura, Hirotaka Teranshi, Masako Yoshida, Yasunori Ueno, Kiyoshi Kasai
-
Publication number: 20140242190Abstract: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analogue thereof; and a pharmaceutically acceptable carrier.Type: ApplicationFiled: May 2, 2014Publication date: August 28, 2014Applicant: Academia SinicaInventors: Lie-Fen SHYUR, Wen-Wan CHAO, Ya-Wen CHENG
-
Patent number: 8815890Abstract: A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent.Type: GrantFiled: August 31, 2007Date of Patent: August 26, 2014Inventors: Robert E. Weinstein, Allan M. Weinstein
-
Patent number: 8815891Abstract: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.Type: GrantFiled: November 11, 2009Date of Patent: August 26, 2014Assignee: Je Il Pharmaceutical Co., Ltd.Inventors: Myung-Hwa Kim, Seung-Hyun Kim, Sae-Kwang Ku, Chun-Ho Park, Bo-Young Joe, Kwang-Woo Chun, In-Hae Ye, Jong-Hee Choi, Dong-Kyu Ryu, Ji-Seon Park, Han-Chang Lee, Ji-So Choi, Young-Chul Kim
-
Publication number: 20140234254Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: February 15, 2014Publication date: August 21, 2014Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLCInventor: Ning Xi
-
Publication number: 20140235599Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject.Type: ApplicationFiled: May 5, 2014Publication date: August 21, 2014Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, OXANA GUERASSIMENKO
-
Publication number: 20140235543Abstract: Methods for identifying a subset of CD8 T cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain CD8 T cells expresses elevated levels of Scin and/or Pla2g4a, with an elevated level indicative of proliferation of the identified CD8 T cells. Also disclosed are methods of diagnosing, monitoring and treating rheumatoid arthritis and transplant rejection, including determining and/or monitoring the expansion of a subset of CD8 T cells by measuring the level of expression of a biomarker in the population of the CD8 T cell subset.Type: ApplicationFiled: February 14, 2014Publication date: August 21, 2014Inventor: Raymond M. Johnson
-
Patent number: 8808716Abstract: The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.Type: GrantFiled: July 20, 2012Date of Patent: August 19, 2014Assignee: Stiefel Research Australia Pty LtdInventor: Leon Loupenok
-
Patent number: 8809363Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.Type: GrantFiled: November 14, 2011Date of Patent: August 19, 2014Assignee: VIIV Healthcare UK LimitedInventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
-
Publication number: 20140221418Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Syed Faiyaz Ahmed Hossainy, Eugene Michal, Thierry Glauser, Connie Kwok, Stephen Dirk Pacetti
-
Publication number: 20140221371Abstract: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.Type: ApplicationFiled: December 23, 2013Publication date: August 7, 2014Inventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Franciso Javier Garcia-Ladona, Wolfgang Wernet
-
Publication number: 20140221329Abstract: Novel mutant ESR1 molecules and uses are disclosed.Type: ApplicationFiled: April 14, 2014Publication date: August 7, 2014Applicant: FOUNDATION MEDICINE, INC.Inventors: Maureen T. Cronin, Garrett Michael Frampton, Doron Lipson, Vincent A. Miller, Gary Palmer, Jeffrey S. Ross, Philip James Stephens, Roman Yelensky
-
Publication number: 20140219929Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.Type: ApplicationFiled: April 7, 2014Publication date: August 7, 2014Applicant: Foamix Ltd.Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
-
Publication number: 20140213532Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidine or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.Type: ApplicationFiled: December 24, 2013Publication date: July 31, 2014Applicant: KAI PHARMACEUTICALS, INC.Inventors: Jonathan B. Rothbard, Paul A. Wender, Leo P. McGrane, Lalitha V.S. Sista, Thorsten A. Kirschberg
-
Publication number: 20140212355Abstract: It is provided herein methods, devices, and compositions for trans-arterial local delivery of therapeutic agent for the treatment of liver cancers.Type: ApplicationFiled: January 28, 2013Publication date: July 31, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Mikael TROLLSAS, Syed Hossainy, John Stankus, Paul Consigny
-
Publication number: 20140213533Abstract: Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3? mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts.Type: ApplicationFiled: January 31, 2014Publication date: July 31, 2014Inventors: Manikkam Suthanthiran, Ruchuang Ding, Joseph E. Schwartz, Abraham Shaked
-
Publication number: 20140212462Abstract: The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.Type: ApplicationFiled: March 31, 2014Publication date: July 31, 2014Applicant: SAMYANG BIOPHARMECEUTICALS CORPORATIONInventors: Hye Won KANG, Min Hyo SEO, Sa Won LEE, Bong Oh KIM, Eun Kyung CHOI, Seong Yun JEONG, Ha Na WOO
-
Publication number: 20140212476Abstract: This invention relates to the targeted delivery of hydrophobic drugs or combinations of hydrophobic drugs with photodynamic therapy agents to vascular lesions by complexation of the drugs to blood serum lipoproteins, which have an affinity for and accumulate in such vascular lesions.Type: ApplicationFiled: March 27, 2014Publication date: July 31, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Dariush Davalian, John Stankus, Yuet Mei Khong, O. Mikael Trollsas, Syed F.A. Hossainy
-
Patent number: 8791097Abstract: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.Type: GrantFiled: April 8, 2008Date of Patent: July 29, 2014Assignee: Wyeth LLCInventors: Gary Dukart, James Joseph Gibbons, Jr., Anna Berkenblit, Jay Marshall Feingold
-
Publication number: 20140206710Abstract: A compound ambroxol hydrochloride composition and a preparation method therefor, which relate to the field of medicine. 0.1%-99.9% by mass of ambroxol hydrochloride and 99.9%-0.1% by mass of scopolamine serving as main ingredients and mannitol are added into water for injection; stir to dissolve, then adjusting to pH 5.0 by adding an NaOH solution; add 0.1% of activated carbon with stirring for 30 minutes; filter out the activated carbon, and then filtering the liquid with 0.45 ?m and 0.22 ?m microporous filter membranes; fill the filtered liquid into a large plate or a vial; send into a lyophilizer, cool to ?40° C., and hold the temperature for 2 hours; warm to ?5° C. to 0° C. slowly to lyophilize the liquid, heat to 35° C.Type: ApplicationFiled: September 28, 2012Publication date: July 24, 2014Applicant: Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.Inventors: Liuyi Wang, Jincan Wang
-
Patent number: 8784860Abstract: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots.Type: GrantFiled: October 27, 2005Date of Patent: July 22, 2014Inventors: Robert Falotico, Jonathan Zhao
-
Patent number: 8785638Abstract: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.Type: GrantFiled: May 17, 2010Date of Patent: July 22, 2014Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Patrick Chaltin, Frauke Christ, Zeger Debyser, Marc De Maeyer, Arnaud Marchand, Damien Marchand, Arnout Voet
-
Patent number: 8785383Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.Type: GrantFiled: April 15, 2013Date of Patent: July 22, 2014Assignee: The Brigham and Women's Hospital, Inc.Inventor: Guo-Ping Shi
-
Publication number: 20140199385Abstract: This invention is directed to a biodegradable, semi-crystalline, phase separated thermoplastic multi-block copolymer, a process for preparing said multi-block copolymer, a composition for the delivery of at least one biological active compound, and to a method for delivering a biologically active compound to a subject in need thereof. A multi-block copolymer of the invention is characterised in that: a) it comprises at least one hydrolysable pre-polymer (A) segment and at least one hydrolysable pre-polymer (B) segment, b) said multi-block copolymer having a Tg of 37° C. or less and a Tm of 110-250° C. under physiological conditions; c) the segments are linked by a multifunctional chain-extender; d) the segments are randomly distributed over the polymer chain; e) at least part of the pre-polymer (A) segment is derived from a water-soluble polymer.Type: ApplicationFiled: July 23, 2012Publication date: July 17, 2014Applicant: INNOCORE TECHNOLOGIES B.V.Inventors: Rob Steendam, Theodorus Adrianus Cornelius Flipsen, Christine Hiemstra, Johan Zuidema
-
Publication number: 20140199236Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.Type: ApplicationFiled: January 9, 2014Publication date: July 17, 2014Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
-
Publication number: 20140199365Abstract: The present invention is directed to stents made of a magnesium alloy degradable under physiological conditions and an outer polymeric coating. Herein, the stents according to the invention can be additionally coated with at least one anti-inflammatory, antiproliferative, antiangiogenic, antirestenotic and/or antithrombogenic active agent.Type: ApplicationFiled: August 15, 2012Publication date: July 17, 2014Applicants: HEMOTEQ AG, MEKO LASERSTRAHL-MATERIALBEARBEITUNGEN E.KInventors: Michael Stekker, Norbert Hort, Frank Feyerabend, Erika Hoffmann, Michael Hoffmann, Roland Horres
-
Patent number: 8778961Abstract: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.Type: GrantFiled: July 6, 2010Date of Patent: July 15, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Mariusz A. Wasik, Leslie M. Shaw
-
Patent number: 8778962Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.Type: GrantFiled: July 11, 2012Date of Patent: July 15, 2014Assignee: Novartis Pharmaceuticals CorporationInventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
-
Publication number: 20140193475Abstract: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.Type: ApplicationFiled: March 10, 2014Publication date: July 10, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Mikael Trollsas, Michael Ngo, Florencia Lim
-
Publication number: 20140194461Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.Type: ApplicationFiled: January 9, 2014Publication date: July 10, 2014Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
-
Publication number: 20140186417Abstract: An aliphatic polyester polymer for stent coating is described.Type: ApplicationFiled: February 20, 2014Publication date: July 3, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: O. Mikael Trollsas, Lothar W. Kleiner, Syed F.A. Hossainy
-
Publication number: 20140186453Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.Type: ApplicationFiled: November 27, 2013Publication date: July 3, 2014Applicant: BIND Therapeutics, Inc.Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
-
Publication number: 20140188057Abstract: A drug-containing patch allows transdermal administration of a drug. The patch features a hydrophobic reservoir containing the drug, where the reservoir has a first surface and a second surface. A drug-impermeable backing overlies the first surface of the reservoir. A release sheet may overlie the second surface of the reservoir. The hydrophobic reservoir contains a drug and a hydrophobic matrix, where the hydrophobic matrix includes a hydrophobic filler in an amount which is effective to adsorb said drug; and a mixture of polyisobutylene and mineral oil. The hydrophobic matrix may contain hydrophobic colloidal silica as the hydrophobic filler. The hydrophobic reservoir layer may serve as a skin-contacting adhesive layer. Alternatively, a release-controlling adhesive layer may serve as the skin-contacting adhesive layer. The release-controlling adhesive layer may contain hydrophobic colloidal silica and a mixture of polyisobutylene and mineral oil.Type: ApplicationFiled: December 31, 2012Publication date: July 3, 2014Applicant: MYLAN, INC.Inventors: Arunprasad Sivaraman, Tyler D. Simmons, Gregory T. Fieldson, Adam C. Sorenson, Jeffrey E. Cortopassi
-
Publication number: 20140187574Abstract: Use of a rapamycin derivative of formula I as defined in the claims for preventing or treating vasculopathies and manifestations of xenotransplantation.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Inventors: Walter Schuler, Hendrik J. Schuurman, Gisbert Weckbecker, Hans-Gunter Zerwes
-
Publication number: 20140186278Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.Type: ApplicationFiled: September 19, 2013Publication date: July 3, 2014Inventor: Patrick Franke
-
Patent number: 8765779Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomers, mixtures of stereoisomers, and salts thereof. This application also relates to compositions comprising compounds of Formula I and uses therefore.Type: GrantFiled: June 21, 2012Date of Patent: July 1, 2014Assignee: Cephalon, Inc.Inventors: Edward R. Bacon, Thomas R. Bailey, Derek D. Dunn, Greg A. Hostetler, Robert J. McHugh, George C. Morton, Gerard C. Rosse, Joseph M. Salvino, Babu G. Sundar, Rabindranath Tripathy
-
Patent number: 8765725Abstract: The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic agent such as fluticasone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, meibomian gland dysfunction or skin inflammation or a respiratory disease (e.g., asthma).Type: GrantFiled: January 7, 2013Date of Patent: July 1, 2014Assignee: Aciex Therapeutics, Inc.Inventors: Thomas Cavanagh, Shikha P. Barman
-
Publication number: 20140179731Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.Type: ApplicationFiled: December 26, 2013Publication date: June 26, 2014Applicant: Veloxis Pharmaceuticals A/SInventors: Robert D. Gordon, Per Holm, Anne-Marie Lademann, Tomas Norling
-
Publication number: 20140179647Abstract: 1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and/or treat certain diseases or conditions.Type: ApplicationFiled: December 17, 2013Publication date: June 26, 2014Applicant: CHIESI FARMACEUTICI S.p.A.Inventors: GABRIELE AMARI, ELISABETTA ARMANI, MAURIZIO DELCANALE
-
Publication number: 20140179725Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.Type: ApplicationFiled: February 24, 2014Publication date: June 26, 2014Inventors: Vivekananda M. Vrudhula, Senliang Pan, Ramkumar Rajamani, John E. Macor, Joanne J. Bronson, Carolyn Diane Dzierba, Susheel Jethanand Nara, Maheswaran Sivasamban Karatholuvhu
-
Patent number: 8759370Abstract: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.Type: GrantFiled: June 9, 2010Date of Patent: June 24, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Mariusz A. Wasik, Leslie M. Shaw
-
Patent number: 8759369Abstract: An inhalable medicament is provided, in particular a new solid-state form of tiotropium bromide. The medicament can be in the form of solid amorphous particles containing an intimate admixture of tiotropium bromide together with a pharmaceutically acceptable co-solid having a glass transition temperature of at least ?50° C., such as a sugar and/or sugar alcohol.Type: GrantFiled: July 3, 2008Date of Patent: June 24, 2014Assignee: Norton Healthcare Ltd.Inventor: Xian-Ming Zeng
-
Patent number: 8759341Abstract: This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.Type: GrantFiled: February 5, 2010Date of Patent: June 24, 2014Assignee: Bayer Intellectual Property GmbHInventors: Martin Michels, Markus Follmann, Alexandros Vakalopoulos, Katja Zimmermann, Mario Lobell, Nicole Teusch, Shendong Yuan